a hrefhttps:www.fiercepharma.commanufacturingsamsung-biologics-spreads-wings-proposed-18b-acquisition-swiss-cdmo-polypeptide hreflangenSamsung Biologics spreads wings with proposed 1.8B acquisition of Swiss CDMO PolyPeptidea

South Korean contract manufacturer Samsung Biologics has tapped into the booming peptide production and weight loss market with plans to buy out Switzerland-based CDMO PolyPeptide for 1.46 billion Swiss francs (1.8 billion).